PBLS — Parabilis Medicines, Inc.

Is PBLS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Parabilis Medicines, Inc. (PBLS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $30.28. The rating moved from Strong Oversold to Oversold on September 25, 2026.

See all oversold Healthcare stocks →

AI analysis

Parabilis Medicines, Inc. (PBLS) sits in a specialty biologics niche where clinical progress and access/pricing outcomes will drive value. Sector-level interest in late-stage biologics and large insider/specialist purchases have supported investor appetite for select names, but a broader risk-off environment and active policy scrutiny on drug pricing constrain upside and increase refinancing/dilution risk. Public filing and social coverage appear limited in the supplied data, leaving uncertainty around cash runway and near-term milestones. Key catalysts are clinical readouts, partnering or funding announcements; primary risks are trial/regulatory failures, pricing headwinds from Medicare negotiation, and competitive displacement.

Key factors

  • Sector-level investor interest in late-stage biologics and visible insider/specialist purchases supporting funding and M&A optionality for select biotech names
  • Macro risk-off sentiment and recent defensive flows that can suppress near-term share-price upside and reduce appetite for new issuance or secondary raises
  • Policy pressure from Medicare drug-price negotiations (IRA) raising potential pricing and access headwinds for specialty therapies
  • Limited public EDGAR/filings and social sentiment data provided, which increases uncertainty about cash runway and near-term financing needs
  • Clinical and pipeline progress remains the primary value driver; upcoming clinical readouts or partnering news would be material catalysts
  • Competitive dynamics in specialty biologics and combo approaches (GLP-1/amylin/other novel combos) that can affect market share and commercial positioning

Risks

  • Clinical trial failure or regulatory setbacks that could materially reduce valuation
  • Downward pricing pressure and reduced reimbursement from Medicare negotiation and payer cost containment actions
  • Need to raise capital in a weak IPO/secondary market leading to dilution at unfavorable terms
  • Competition from large pharma and well-funded specialty players developing combination therapies or alternative mechanisms
  • Near-term market volatility and low-volume trading days that can amplify price moves
  • Information asymmetry due to limited public reporting and social/research coverage increases execution risk for investors
  • Geopolitical or macro developments that sustain risk-off sentiment and limit positive re-rating opportunities

See today's live rating, score and targets

Members see the live hourly rating for PBLS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.